X

pharma stocks

Spinraza helps Biogen beat the street in Q1

A month after announcing the withdrawal from its Phase 3 Alzheimer’s trials, biopharma firm Biogen (NASDAQ: BIIB) on Wednesday reported…

Biocept narrows loss in Q4

Biocept (BIOC) narrowed its loss in the fourth quarter, beating analyst estimates. However, sales failed to impress the street. Shares…

Why Amarin stock is rallying today

Amarin Corporation (NASDAQ: AMRN) shares got a major boost during the pre-market hours of Thursday after it said the American…

Earnings preview: What’s on the cards for Biocept in Q4

Biocept (BIOC) is scheduled to report fourth quarter and full year 2018 results on March 28, Thursday, after the regular…

Earnings: Affimed cuts down losses in 2018

Affimed N.V. (AFMD), a clinical stage biopharmaceutical company that focuses on oncology drugs, Wednesday reported net losses that narrowed in…

Onconova Therapeutics cuts down losses in 2018

Onconova Therapeutics (ONTX), a Phase 3 biopharmaceutical company that focuses on developing cancer drugs, Tuesday posted a narrowed loss in…

What is NASH and which biotech firms are vying for the first-mover status

NASH, or Nonalcoholic steatohepatitis, is undeniably a golden goose in the pharma space. The biggest corporate attraction towards this liver…

Novavax misses Q4 estimates, shares slip

NVAX Earnings Transcripts    NVAX Earnings Calendar Clinical-stage vaccine company Novavax (NVAX) reported a loss of 13 per share in…

Earnings: Trevena slips on wider-than-expected Q4 loss

Trevena Inc (TRVN) Wednesday reported fourth-quarter losses that were wider than analysts’ estimates, sending its shares down 5.4% during pre-market…

Portola Pharmaceuticals rises on strong Q4 earnings

Shares of Portola Pharmaceuticals (PTLA) gained 5.6% during pre-market trading on Friday, after the company posted a loss of $1.04…

Amarin shares jump 14% on rumors over Novartis interest

Shares of Amarin Corp (AMRN) gained up to 14% during the regular trading hours on Friday as rumors of an…

CVS Health Q4 earnings preview: What to expect

CVS Health Corporation (CVS) is scheduled to report fourth-quarter earnings results before the regular trading hours on Wednesday, February 20.…

Earnings: Oncology unit drives AstraZeneca topline higher in Q4

AstraZeneca Plc (AZN) reported a 22% dip in earnings for the fourth quarter to 82 cents per share, weighed down…

Gilead’s credibility takes a hit on massive NASH-drug failure, rivals jump

Shares of Gilead Sciences (GILD) have tumbled 20% in the past 52 weeks on numerous reasons including weaker-than-expected quarterly results…

Earnings: Array BioPharma delivers strong Q2 results, investors cheer

Array BioPharma (ARRY) reported 44% jump in second-quarter revenue to $82.5 million, driven by higher product sales and recognition of…

Earnings: Pfizer edges past Q4 estimates, shares dip on weak outlook

Pfizer (PFE) reported a better-than-expected 2% increase in fourth-quarter revenues to $13.9 billion. Earnings rose to 64 cents per share…

Bristol-Myers Squibb reports Q4 earnings on Jan 24. What to expect

Only two weeks after announcing its massive acquisition of Celgene Corporation, drug-maker Bristol-Myers Squibb (BMY) is all set to report…

Why Ligand Pharma, Viking Therapeutics tumbled yesterday, but is gaining today

Shares of Ligand Pharmaceuticals (LGND) took a beating on Wednesday after a bearish report by Citron Research led by short-seller…

In a massive deal, Eli Lilly acquires Loxo Oncology

Eli Lilly and Company (LLY) on Monday announced that it would acquire a small biopharmaceutical startup that develops cancer treatment,…

Johnson & Johnson dips on revenue decline in India

Johnson & Johnson (JNJ) shares fell 1% on Thursday after the company reported a 3% sales dip in India in…

Johnson & Johnson will spend more time in court in 2019

The tainted talc has been snowballing into a gigantic threat since 2016, and things are not looking good as Johnson…